VRDN logo

VIRIDIAN THERAPEUTICS INC

VRDNNASDAQ
πŸ† #1488 by market capEarnings Feb 24 Β· PostUS Equity
β€”β€”
Quote unavailable
πŸ””
Track VRDN
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$3.40B
Small Cap
πŸ“ˆRevenue Growth (YoY)
23359.9%
High Growth
πŸ“ŠGross Margin
93.0%
High
πŸ’΅FCF Margin
-1305.4%
Thin
βš–οΈP/S Ratio
129.3x
Expensive
Otter Score
76
Strong
No chart data available for VRDN.

Trading Snapshot

Day Range
β€”
52-Week Range
$13.18 – $34.29
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
113.6M
Next Earnings
2027-02-24

Fundamentals Snapshot

Annual Revenue
$71M
Last Q Revenue
$26M
P/E Ratio
-7.7
P/S Ratio
129.3x
EPS (TTM)
$-4.00
Dividend Yield
0.00%
Dilution (1yr)
+5.9%
VRDN logo

VIRIDIAN THERAPEUTICS INC

VRDN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$71Mβ–² +23359.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%β–² +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$363Mβ–² +21.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$277Mβ–² +18.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
84.8Mβ–² +5.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$162Mβ–² +$83M YoY
StockOtter Β· stockotter.space

About VIRIDIAN THERAPEUTICS INC

Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
76/100

Analyst Ratings

β“˜
Consensus
Buy
23 analysts
Strong Buy8
Buy14
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

News unavailable.